Quarterly report pursuant to Section 13 or 15(d)

Revenue and Accounts Receivable - Additional Information (Detail)

v3.5.0.2
Revenue and Accounts Receivable - Additional Information (Detail)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
USD ($)
company
Sep. 30, 2015
USD ($)
company
Sep. 30, 2016
USD ($)
company
Sep. 30, 2015
USD ($)
company
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 6,750 $ 4,001 $ 19,819 $ 12,556
Number of companies that accounted for approximately 10% or more of revenue | company 1 2 1 2
Payor | Testing Volume | Clinical Testing        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 39.00% 59.00% 31.00% 80.00%
Payor | Testing Volume | Community Hospitals        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 6.00% 27.00% 7.00% 31.00%
Payor | Sales | Customer One | 10% or More Clinical Revenue        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark 18.00% 15.00% 10.00% 23.00%
Payor | Sales | Customer Two | 10% or More Clinical Revenue        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Percentage of benchmark   11.00%   11.00%
Clinical Services        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 2,687 $ 1,150 $ 7,685 $ 3,274
Clinical Services | Response Genetics, Inc.        
Accounts, Notes, Loans and Financing Receivable [Line Items]        
Revenue $ 1,481   $ 4,610